ExonHit Eyes Affy Platform for Alzheimer’s Test; Could Launch Dx As Early As 2009 | GenomeWeb
French diagnostics firm ExonHit Therapeutics said last week that it has developed a prototype based on the Affymetrix GeneChip Platform for a blood-based test to identify patients suffering from Alzheimer’s disease.
ExonHit said it expects it to have the test certified and ready to market as early as 2009, placing it on a similar timeline as several firms that have committed to developing diagnostics on the Affy platform, including BioMérieux, Roche Diagnostics, Epigenomics, Almac Diagnostics, and others.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.